iiinova — where your digital self keeps evolving

Vascular Pharmacology @vaspharma.bsky.social · 20/09/2026

Our new study presents an adjustable EPV ligation model for graded control of portal venous stenosis and hemodynamic stress. It reveals structural and nuclear remodeling and enables the study of mechanosensitive adaptation doi.org/10.1016/j.vp...

000

Vascular Pharmacology @vaspharma.bsky.social · 10/09/2026

Could lymphedema progression be stopped before fibrosis takes hold? Lanifibranor (IVA337) improved lymphatic drainage and vessel integrity while reducing inflammation and fibrosis by suppressing TGFβ/SMAD2/3 signaling—highlighting pan-PPAR activation as a promising early therapeutic strategy

200

Vascular Pharmacology @vaspharma.bsky.social · 03/09/2026

Our newly published research article reports aquaporin 1 as a key conduit facilitating H₂O₂ influx and subsequent NO efflux during endothelium-dependent relaxation in regulating vascular tone. Read more at doi.org/10.1016/j.vp...

000

Vascular Pharmacology @vaspharma.bsky.social · 27/08/2026

Our new article reports the novel role of Paeoniflorin in stabilizing the atherosclerotic plaque by inhibiting endoplasmic reticulum stress-induced VSMC phenotypic switching via activating the AMPK/PPARδ signaling pathway. doi.org/10.1016/j.vp...

000

Vascular Pharmacology @vaspharma.bsky.social · 26/08/2026

Beyond the lungs: formoterol fumarate delivers broad cardiometabolic protection in ApoE KO mice, lowering lipids and atherosclerotic plaque burden, while improving endothelial, cardiac, and liver function. MRI confirms reduced hepatic fat and better cardiac performance. #Atherosclerosis #CVD.

100

Vascular Pharmacology @vaspharma.bsky.social · 21/08/2026

High glucose pushes endothelial cells toward ferroptosis, but circFBXO7 may be a key switch. By promoting TFCP2 degradation, circFBXO7 drives oxidative stress, lipid peroxidation, and vascular injury. The circFBXO7–TFCP2 axis reveals a new target in diabetic vascular dysfunction. #Diabetes.

100

Vascular Pharmacology @vaspharma.bsky.social · 14/08/2026

Our recent review highlights molecular pathology and genetic advances in diabetic cardiac autonomic neuropathy (DCAN) and the need for innovative CRISPR and gene therapy strategies for better diagnosis and treatment of DCAN. doi.org/10.1016/j.vp...

010

Vascular Pharmacology @vaspharma.bsky.social · 14/08/2026

A heart attack can echo to the brain. Low-density lipoprotein receptor-related protein 5 (LRP5) deficiency worsens cardiac injury and neuronal vulnerability, while TNF-α supports microglial survival via LRP5–NF-κB signaling. #AMI #Neuroinflammation #LRP5 #NFkB. doi.org/10.1016/j.vp...

000

Vascular Pharmacology @vaspharma.bsky.social · 03/08/2026

Our new study evaluated magnetically responsive PLGA-MNPs for a stent-targeted drug delivery platform. Magnetic field exposure increased nanoparticle attachment to stents and drug detection in release assays. doi.org/10.1016/j.vp...

010

Vascular Pharmacology @vaspharma.bsky.social · 28/07/2026

Aspirin may do more than stop platelets. Could it also reshape fibrin clots? This review explores how fibrinogen acetylation may alter clot structure, cross-linking, permeability, and breakdown, and why the clinical impact of this extra-platelet effect remains uncertain. #Thrombosis

100

Vascular Pharmacology @vaspharma.bsky.social · 27/07/2026

New Review. This review explores the CAV1–EV axis as a key link between endothelial dysfunction, vascular aging, cardiovascular disease, and frailty, highlighting its potential as a biomarker and therapeutic target. #VascularBiology #Aging #CardiovascularResearch #Frailty doi.org/10.1016/j.vp...

000

Vascular Pharmacology @vaspharma.bsky.social · 27/07/2026

Our recently published study highlights that ouabain's vascular effects depend on the contracting stimulus. Na⁺/K⁺-ATPase–Src pathway enhances Ca²⁺ sensitization, while BKCa channels act as a brake on excessive vasoconstriction. doi.org/10.1016/j.vp...

000

Vascular Pharmacology @vaspharma.bsky.social · 10/07/2026

Not all TAVR patients carry the same stroke risk. In severe PAD patients treated via transfemoral access, combining CHA₂DS₂-VASc with the HOSTILE anatomical score improved prediction of 30-day CVA, highlighting the value of integrating clinical and anatomical risk for smarter prevention. #Cardiology

100

Vascular Pharmacology @vaspharma.bsky.social · 06/07/2026

000

Vascular Pharmacology @vaspharma.bsky.social · 30/06/2026

Our new review highlights the importance of endothelial interface and transport barrier in vascularized tumor organoid models. The future lies in quantifying vascular transport, AI-driven analysis, and patient-specific models for precision oncology doi.org/10.1016/j.vp...

000

Vascular Pharmacology @vaspharma.bsky.social · 30/06/2026

Cannabinoids can relax blood vessels, but is PPARγ truly involved, or are off-target drug effects and ion channels driving the response? This focused review challenges assumptions, weighs the evidence, and calls for better tools to decode vascular cannabinoid signaling. #VascularBiology'

100

Vascular Pharmacology @vaspharma.bsky.social · 10/06/2026

Our recently published review highlights the importance of CMR in acute myocardial infarction (AMI) care. Emphasis on faster imaging, AI-assisted analysis, and integration with CT could be the future in clinical care after AMI doi.org/10.1016/j.vp...

000

Vascular Pharmacology @vaspharma.bsky.social · 04/06/2026

Sex-specific differences in lineage-derived VSMCs may help explain why Stanford type A TAAD occurs more often in men. Female VSMCs showed enhanced ECM-related gene expression linked to greater mechanical resilience. #TAAD #AorticAneurysm #VascularBiology #CardiovascularResearch #scRNAseq

100

Vascular Pharmacology @vaspharma.bsky.social · 04/06/2026

New review: m6A RNA methylation plays a key role in VSMC phenotypic switching and vascular disease pathogenesis. Targeting m6A writers, erasers, and readers may offer new therapeutic opportunities for vascular disorders. #VascularBiology #Epigenetics #RNAbiology #m6A #VSMC #CardiovascularResearch

110

Vascular Pharmacology @vaspharma.bsky.social · 04/06/2026

Our recently published study reveals that the 21-amino-acid C-terminal domain of CaMKIIδ2 drives vascular smooth muscle cell migration via FYN kinase, a potential target for pathological vascular remodeling. 10.1016/j.vph.2026.107651

000

Vascular Pharmacology @vaspharma.bsky.social · 04/06/2026

Impaired RV-PA coupling during exercise is linked to pulmonary congestion in HFrEF/HFmrEF patients, especially in those with elevated peak PAPs. Findings highlight a key mechanism driving exercise-induced EVLW increase #HeartFailure #Cardiology #Echocardiography #PulmonaryHypertension #HFmrEF #HFrEF

100

Vascular Pharmacology @vaspharma.bsky.social · 14/05/2026

Heavy legs, swelling, pain, can venoactive drugs improve chronic venous disease care? This expert review spotlights micronized purified flavonoid fraction as a leading option for easing symptoms and improving quality of life, while weighing evidence for other therapies. #VascularPharma #VenousHealth

100

Vascular Pharmacology @vaspharma.bsky.social · 14/05/2026

New hope for small abdominal aortic aneurysms? This meta-analysis shows anti-inflammatory therapies not only slowed AAA progression in mice, but were the only treatments linked to reduced rupture risk. A promising step toward translational AAA therapy.#AAA #VascularPharmacology #Inflammation #Cardio

110

Vascular Pharmacology @vaspharma.bsky.social · 14/05/2026

Does pyroptosis drive thoracic aortic dissection? In a BAPN mouse model, knockout of Caspase-11 or GSDMD failed to alter TAD outcomes, challenging assumptions about non-canonical pyroptosis in aortic disease. Negative results, big implications. #VascularBiology #AorticDissection #Pyroptosis #Cardio

110

Vascular Pharmacology @vaspharma.bsky.social · 08/05/2026

What happens when the lung can’t utilize more capillaries during exercise? First direct measurements in severe pulmonary arterial hypertension show impaired functional capillary surface area recruitment, even at maximal dyspnea. #VascularPharmacology #PAH #PulmonaryHypertension #ExercisePhysiology

100

Vascular Pharmacology @vaspharma.bsky.social · 05/05/2026

Our new review analyzes the mechanistic link between chronic venous insufficiency (CVI) and cardiovascular risk, proposing to integrate proactive cardiovascular screening for CVI patients to improve long-term prognosis. doi.org/10.1016/j.vp...

010

Vascular Pharmacology @vaspharma.bsky.social · 05/05/2026

A prospective study analyzed long-term survival in a real-world heart failure cohort and identified significant gaps in guideline-directed therapy. Bridging guideline recommendations and practice through early risk stratification and multicomponent therapy is key to improving survival.

100

Vascular Pharmacology @vaspharma.bsky.social · 18/04/2026

Angiogenesis research is entering a new era 🧬 Our latest review maps in vitro, ex vivo & in vivo assays and integrates AI imaging, spatial transcriptomics & CRISPR to guide smarter assay selection. A decision matrix + algorithm for reproducible, translational science.

100

Vascular Pharmacology @vaspharma.bsky.social · 09/04/2026

NEW article 🎉 mTORC1 (via RAPTOR) rewires amino acid metabolism in lymphatic endothelial cells, disrupting glutaminolysis, altering BCAA handling, and impacting vessel formation. Metabolism is central to lymphatic biology. #mTORC1 #Lymphatics #Metabolism #VascularBiology doi.org/10.1016/j.vp...

000

Vascular Pharmacology @vaspharma.bsky.social · 06/04/2026

Extracellular vesicles (EVs) link vascular inflammation and coagulation. Our recently published review article proposes a unified mechanistic model that defines the common molecular drivers of EV thrombogenicity, advancing EVs towards precise clinical tools. doi.org/10.1016/j.vp...

000

Vascular Pharmacology @vaspharma.bsky.social · 30/03/2026

Our systematic review on sodium nitroprusside highlights its pharmacology, clinical applications, and safety considerations in cardiovascular health. It also emphasizes the need for individualized dosing strategies to maximize long-term clinical impact and minimize toxicity. doi.org/10.1016/j.vp...

000

Vascular Pharmacology @vaspharma.bsky.social · 16/03/2026

Benzo[a]pyrene (BaP) worsens atherosclerosis via SPP1-driven macrophage inflammation and lipid dysregulation. Integrative omics with cellular validation reveal SPP1 as a potential target in pollution-related vascular disease. #Atherosclerosis #EnvironmentalHealth #SPP1 doi.org/10.1016/j.vp...

000

Vascular Pharmacology @vaspharma.bsky.social · 24/02/2026

New research shows low-dose colchicine disrupts macrophage microtubules,slashes cell footprint & matrix degradation, and reduces motility, uncovering a potential mechanism behind its CV protection in atherosclerosis. Inflammation meets cytoskeleton #Atherosclerosis#Colchicine doi.org/10.1016/j.vp...

000

Vascular Pharmacology @vaspharma.bsky.social · 20/02/2026

Preeclampsia may shape brain health long after pregnancy. This review explores how angiogenic imbalance, endothelial dysfunction, and AD-related proteins could link PE to later cognitive decline, highlighting pathways for potential drug repurposing. #Preeclampsia #Alzheimers #WomensHealth

111

Vascular Pharmacology @vaspharma.bsky.social · 11/02/2026

Can routine MRA predict which brain aneurysms will rupture? Our latest article shows how patient-specific CFD tool maps hidden blood-flow forces, revealing shear-stress patterns that distinguish stable from high-risk lesions, advancing noninvasive, personalized care #Neurosci #CFD #StrokePrevention

100

Vascular Pharmacology @vaspharma.bsky.social · 06/02/2026

Our review examines chamber-specific expression and function of ion channels in the human heart. This comprehensive and integrative analysis could serve as a basis for developing therapeutic strategies for improved patient care. doi.org/10.1016/j.vp...

000

Vascular Pharmacology @vaspharma.bsky.social · 05/02/2026

New article: This study reveals that EndMT contributes to atherosclerosis by generating osteogenic- and chondrogenic-like cells, linking endothelial dysfunction to vascular calcification in disease #EndMT #Atherosclerosis #VascularBiology #CardiovascularScience doi.org/10.1016/j.vp...

000

Vascular Pharmacology @vaspharma.bsky.social · 04/02/2026

A new observational study using INSPECTIO supports the effectiveness of guideline-directed therapy and regular risk assessment to optimize treatment strategies in Pulmonary Arterial Hypertension. #PAH #ClinicalResearch #INSPECTIO #ObservationalStudy #Macitentan #Selexipag doi.org/10.1016/j.vp...

000

Vascular Pharmacology @vaspharma.bsky.social · 02/02/2026

Announcement: Vascular Pharmacology announces the 2025 Best Cover Image Award winner: “Cdc42 is crucial for mural cell migration, proliferation and patterning of the retinal vasculature” (Álvarez-Aznar et al.) Congratulations! www.sciencedirect.com/journal/vasc... #VascularPharmacology #BestCover

000

Vascular Pharmacology @vaspharma.bsky.social · 02/02/2026

Announcement: Vascular Pharmacology is pleased to announce the winners of 2025 Young Scientist Award: Dr. Konrad Stępień (Clinical Research) and Dr. Francesca Vacante (Basic Research). The official announcement is live: www.sciencedirect.com/journal/vasc... #VascularPharmacology #YoungScientistAward

sciencedirect.com

News - Vascular Pharmacology | ScienceDirect.com by Elsevier

Read the latest articles of Vascular Pharmacology at ScienceDirect.com, Elsevier’s leading platform of peer-reviewed scholarly literature

000

Vascular Pharmacology @vaspharma.bsky.social · 22/01/2026

A newly published systematic review & meta-analysis reveals that exercise pulmonary hypertension could be a promising endpoint for evaluating pharmacological therapies for chronic thromboembolic pulmonary disease without resting pulmonary hypertension. doi.org/10.1016/j.vp...

000

Vascular Pharmacology @vaspharma.bsky.social · 15/01/2026

Sotatercept has been found effective in PAH treatment. This review explores Sotatercept's pleiotropic benefits, particularly in erythropoiesis, muscle atrophy, and bone loss, and suggests how it could be transformative for PAH therapy. doi.org/10.1016/j.vp...

010

Vascular Pharmacology @vaspharma.bsky.social · 16/12/2025

Vascular smooth muscle cells are the underrated shapeshifters driving plaque evolution. Our new review unpacks how mechanics, molecular signals, and RNA regulation push vSMCs toward phenotypes that fuel plaque growth and vulnerability. #Atherosclerosis #VascularBiology #SmoothMuscleCells

110

Vascular Pharmacology @vaspharma.bsky.social · 16/12/2025

New Italian multicenter registry data reveal how pulmonary arterial hypertension (PAH) is diagnosed and treated in real life, early detection, comprehensive workups, and guideline-driven care. A sharper picture of patient needs. #PAH #PulmonaryHypertension #RealWorldData #PHResearch #CardioScience'.

100

Vascular Pharmacology @vaspharma.bsky.social · 09/12/2025

New study reveals that microplastics can worsen pulmonary hypertension by promoting EndMT, inflammation, and histone lactylation in endothelial cells. Key genes like TNFRSF11B and SGK1 emerge as potential therapeutic targets to counter PH progression. #PulmonaryHypertension #EndMT #Microplastics

100

Vascular Pharmacology @vaspharma.bsky.social · 09/12/2025

New review explores amylin receptor agonists (AMYRAs) as next generation therapies for obesity, offering benefits that go beyond weight loss. With advances in AMYR biology, dual agonism, and delivery tech, AMYRAs may redefine precision obesity care by 2030. #ObesityResearch #MetabolicHealth #Amylin

100

Vascular Pharmacology @vaspharma.bsky.social · 09/12/2025

New review highlights how adaptive immunity shapes the development of aortic aneurysm and dissection (AAD) — from antigen activation to aortic damage. Understanding these immune pathways could unlock targeted therapies for this deadly condition. #AorticDisease #Immunology #CardioResearch #AAD

110

Vascular Pharmacology @vaspharma.bsky.social · 05/12/2025

New review: Nebivolol through NO-mediated vasodilation, shows promise in heart failure. Evidence highlights vascular, metabolic, and clinical benefits, with potential in personalized HF therapy. doi.org/10.1016/j.vp...

000

Vascular Pharmacology @vaspharma.bsky.social · 11/11/2025

New study shows 17β-estradiol induces NOS-dependent vasorelaxation in mouse aorta, with subtle sex- differences among ER subtypes. PI3K inhibition enhances relaxation by reducing MLC phosphorylation. doi.org/10.1016/j.vp...

000

Vascular Pharmacology @vaspharma.bsky.social · 03/11/2025

Does vessel size truly dictate soluble guanylate cyclase sensitivity? A new commentary on Lubomirov et al. suggests enhanced cinaciguat responses in smaller arteries may reflect hypoxia–reoxygenation and pathological context, not intrinsic diameter effects. #vascularbiology #NOcGMP #sGC

doi.org

Redirecting

000